Alimera’s Iluvien Suffers Same Demise As Lucentis; NICE Rejects For DME
Executive Summary
Triumphant in Europe at the regulatory stage, Alimera finds that health technology assessment is a different ball game, as NICE turns down Iluvien for diabetic macular edema on two counts.
You may also be interested in...
NICE Clears Alimera’s Iluvien For DME In Patients With Artificial Lens
Alimera Sciences’s Iluvien gets reimbursement clearance in the U.K. for diabetic macular edema patients unresponsive to other therapies with the help of a price discount and the lack of cataract side effects by limiting its use to patients with artificial lens.
Lucentis Price Concessions Win Partial Victory; NICE Clears Drug With Restrictions
Britain's cost watchdog NICE changed its mind on Lucentis, and now recommends it for treating diabetic macular edema, after Novartis offered a steeper discount – but the eye drug’s price tag remains high, so only a subgroup of British patients will receive it.
Genentech Says Lucentis DME Product Will Ship Shortly
FDA approves lower, monthly 0.3 mg dose of injectable Lucentis for diabetic macular edema, the regimen Genentech had suggested was most appropriate. Questions remain about the commercial picture, considering competition from the similar but much cheaper Avastin.